Citigroup
PRTK

Citigroup’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Citigroup’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$4 – 5983
2022
Q4 		$4 Sell
2
-629
-100% -$1.57K ﹤0.01% 5733
2022
Q3 		$2K Sell
631
-682
-52% -$1.7K ﹤0.01% 5569
2022
Q2 		$3K Sell
1,313
-1,694
-56% -$3.7K ﹤0.01% 5826
2022
Q1 		$9K Sell
3,007
-11,657
-79% -$43.9K ﹤0.01% 5606
2021
Q4 		$66K Buy
14,664
+6,075
+71% +$28.8K ﹤0.01% 4942
2021
Q3 		$42K Buy
8,589
+1,521
+22% +$8.38K ﹤0.01% 4837
2021
Q2 		$48K Buy
7,068
+1,248
+21% +$10.1K ﹤0.01% 4855
2021
Q1 		$41K Sell
5,820
-7,515
-56% -$54.1K ﹤0.01% 4820
2020
Q4 		$83K Buy
13,335
+9,253
+227% +$54.5K ﹤0.01% 5690
2020
Q3 		$22K Sell
4,082
-3,539
-46% -$17.5K ﹤0.01% 6143
2020
Q2 		$40K Sell
7,621
-6,606
-46% -$29.3K ﹤0.01% 6162
2020
Q1 		$45K Buy
14,227
+3,469
+32% +$12.8K ﹤0.01% 6065
2019
Q4 		$43K Buy
10,758
+4,652
+76% +$16.1K ﹤0.01% 6435
2019
Q3 		$27K Buy
6,106
+1,304
+27% +$5.21K ﹤0.01% 6553
2019
Q2 		$19K Buy
4,802
+1,195
+33% +$5.68K ﹤0.01% 7110
2019
Q1 		$19K Buy
3,607
+54
+2% +$349 ﹤0.01% 6999
2018
Q4 		$18K Sell
3,553
-4,252
-54% -$32.3K ﹤0.01% 6933
2018
Q3 		$75K Buy
7,805
+7,640
+4,630% +$77.1K ﹤0.01% 6177
2018
Q2 		$2K Sell
165
-318
-66% -$3.6K ﹤0.01% 7487
2018
Q1 		$6K Buy
483
+31
+7% +$462 ﹤0.01% 7180
2017
Q4 		$8K Sell
452
-1,407
-76% -$29.4K ﹤0.01% 7127
2017
Q3 		$47K Sell
1,859
-5,969
-76% -$139K ﹤0.01% 6029
2017
Q2 		$189K Buy
7,828
+7,788
+19,470% +$172K ﹤0.01% 4848
2017
Q1 		$1K Buy
+40
New +$630 ﹤0.01% 7124
2016
Q2 		– Sell
-8,525
Closed -$129K – 7534
2016
Q1 		$129K Buy
8,525
+4,816
+130% +$73.7K ﹤0.01% 5472
2015
Q4 		$71K Buy
3,709
+3,707
+185,350% +$70.8K ﹤0.01% 5656
2015
Q3 		$0 Sell
2
-159
-99% -$3.96K ﹤0.01% 7817
2015
Q2 		$4K Buy
+161
New +$4.57K ﹤0.01% 6910
2014
Q3 		– Sell
-2
Closed – – 7363
2014
Q2 		$0 Sell
2
-4
-67% -$130 ﹤0.01% 7369
2014
Q1 		$0 Sell
6
-1
-14% -$39 ﹤0.01% 7253
2013
Q4 		$0 Buy
7
+6
+600% +$255 ﹤0.01% 7197
2013
Q3 		$0 Buy
+1
New +$36 ﹤0.01% 7035

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Citigroup's PRTK Position: Q1 2023 in Review

Citigroup sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 2 shares — an estimated $4 sold.

Citigroup first reported a position in PRTK in Q3 2013 and held it in 32 quarters. The position peaked at $189K in Q2 2017. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.

  • Citigroup reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 2 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.
  • Citigroup first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2013 and held it in 32 quarters.
  • Citigroup's Paratek Pharmaceuticals, Inc. position peaked at $189K in Q2 2017.
  • 63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.